COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
The novel combination of cabozantinib plus atezolizumab exhibited clinical activity in advanced UC that is cis-eligible, cis-ineligible, or previously treated with platinum-containing chemotherapy; clinical activity in previous ICI-treated UC was modest. The toxicity profile was consistent with that previously reported for the combination.
Authors
- Martin Schwickart
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Yohann Loriot (ORCID: https://orcid.org/0000-0002-8338-1739)
- Carla M.L. van Herpen (ORCID: https://orcid.org/0000-0001-5130-5451)
- Ralph J. Hauke (ORCID: https://orcid.org/0000-0002-0243-7279)
- Svetlana Andrianova
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Kevin D. Courtney (ORCID: https://orcid.org/0000-0001-6273-3144)
- Bradley A. McGregor (ORCID: https://orcid.org/0000-0002-8298-0289)
- Ramu Sudhagoni
- Ulka N. Vaishampayan (ORCID: https://orcid.org/0000-0001-5800-4571)
- Cristina Suárez (ORCID: https://orcid.org/0000-0002-0502-5528)
- Lance C. Pagliaro (ORCID: https://orcid.org/0000-0002-4209-3394)
- Andrea Necchi (ORCID: https://orcid.org/0000-0002-3007-2756)
- Thomas B. Powles (ORCID: https://orcid.org/0000-0001-7760-4724)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
- Robert Dreicer (ORCID: https://orcid.org/0000-0002-0552-6912)
- Parminder Singh (ORCID: https://orcid.org/0000-0002-8548-6948)
Institutions
- Radboud University Nijmegen (NL)
- Exelixis (United States) (US)
- Vita-Salute San Raffaele University (IT)
- University of Utah (US)
- Barts Health NHS Trust (GB)
- Université Paris-Saclay (FR)
- University of Michigan (US)
- Huntsman Cancer Institute (US)
- Institut Gustave Roussy (FR)
- WinnMed (US)
- Radboud University Medical Center (NL)
- Hospital Universitario 12 De Octubre (ES)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- Vall d'Hebron Hospital Universitari (ES)
- Mayo Clinic in Florida (US)
- Nebraska Cancer Specialists (US)
- Vall d'Hebron Institute of Oncology (ES)
- University of Virginia Cancer Center
- University of Virginia (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1200/jco-24-01675
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Celgene
- Merck KGaA
- Exelixis
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Incyte
- Calithera Biosciences
- AstraZeneca España
- Seagen
- Eisai
- Astellas Pharma
- Ipsen
- EUSA Pharma
- Genentech
- Samsung
- EMD Serono
- Daiichi Sankyo Europe